Drug Search Results
More Filters [+]

Triamterene

Alternative Names: triamterene, dyrenium, dyazide, maxzide, maxzide-25
Latest Update: 2023-07-18
Latest Update Note: Clinical Trial Update

Product Description

Triamterene is a medication used in the management and treatment of edematous states. It is in the potassium-sparing diuretics class of drugs. This activity outlines the indications, action, and contraindications for triamterene as a valuable agent in managing fluid retaining states and hypertension. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK557650/)

Mechanisms of Action: Sodium Channel Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Austria | Bangladesh | Bulgaria | Canada | Chile | Colombia | Dominican Republic | Egypt | France | Hong Kong | India | Ireland | Morocco | Netherlands | New Zealand | Pakistan | Peru | Russia | South Africa | Spain | Taiwan | Tunisia | Turkey | United Kingdom | United States | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Triamterene

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title